New & Noteworthy

May 2018

Meropenem-Vaborbactam Panel Gains FDA 510(k) Clearance

BD

BD introduces the ability to execute in vitro rapid identification (ID) and antimicrobial susceptibility testing (AST) for meropenem-vaborbactam in a new panel for the BD Phoenix Automated Microbiology System, which detects resistance in Enterobacteriaceae, Non-Enterobacteriaceae, and most gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus. The BD Phoenix allows clinical microbiology laboratories to rapidly and accurately test antimicrobial resistances or susceptibilities. The results for ID and AST are powered through an oxidation-reduction indicator with turbidity measurement for growth detection, as well as full on-panel antimicrobial concentrations and the BDXpert system for data analysis.

Request More Information

Current Issue